TY - JOUR
T1 - Computing Univariate Neurodegenerative Biomarkers with Volumetric Optimal Transportation
T2 - A Pilot Study
AU - the Alzheimer's Disease Neuroimaging Initiative
AU - Tu, Yanshuai
AU - Mi, Liang
AU - Zhang, Wen
AU - Zhang, Haomeng
AU - Zhang, Junwei
AU - Fan, Yonghui
AU - Goradia, Dhruman
AU - Chen, Kewei
AU - Caselli, Richard J.
AU - Reiman, Eric M.
AU - Gu, Xianfeng
AU - Wang, Yalin
N1 - Funding Information:
This work was partially supported by National Health Institutes (R21AG043760 and RF1AG051710 to LM, WZ, YF and YW, R01EB025032 to HZ and YW, U54EB020403 to YF and YW, R01AG031581 and P30AG19610 to RJC and EMR, 3R01HL128818-04S1 to YW), National Science Foundation (DMS-1413417 and IIS-1421165 to LM, WZ, YF, and YW) and Arizona Alzheimers Consortium (to KC, RJC, EMR and YW). Data collection and sharing for this project was funded by the ADNI (National Institutes of Health Grant U01 AG024904) and DOD ADNI (Department of Defense award number W81XWH-12-2-0012). ADNI is funded by the National Institute on Aging, the National Institute of Biomedical Imaging and Bioengineering, and through generous contributions from the following: AbbVie, Alzheimer?s Association; Alzheimer?s Drug Discovery Foundation; Araclon Biotech; BioClinica, Inc.; Biogen; Bristol-Myers Squibb Company; CereSpir, Inc.; Cogstate; Eisai Inc.; Elan Pharmaceuticals, Inc.; Eli Lilly and Company; EuroImmun; F. Hoffmann-La Roche Ltd. and its affiliated company Genentech, Inc.; Fujirebio; GE Healthcare; IXICO Ltd.; Janssen Alzheimer Immunotherapy Research & Development, LLC.; Johnson & Johnson Pharmaceutical Research & Development LLC.; Lumosity; Lundbeck; Merck & Co., Inc.; Meso Scale Diagnostics, LLC.; NeuroRx Research; Neurotrack Technologies; Novartis Pharmaceuticals Corporation; Pfizer Inc.; Piramal Imaging; Servier; Takeda Pharmaceutical Company; and Transition Therapeutics. The Canadian Institutes of Health Research is providing funds to support ADNI clinical sites in Canada. Private sector contributions are facilitated by the Foundation for the National Institutes of Health (www.fnih.org ). The grantee organization is the Northern California Institute for Research and Education, and the study is coordinated by the Alzheimer?s Therapeutic Research Institute at the University of Southern California. ADNI data are disseminated by the Laboratory for Neuro Imaging at the University of Southern California.
Funding Information:
Data collection and sharing for this project was funded by the ADNI (National Institutes of Health Grant U01 AG024904) and DOD ADNI (Department of Defense award number W81XWH-12-2-0012). ADNI is funded by the National Institute on Aging, the National Institute of Biomedical Imaging and Bioengineering, and through generous contributions from the following: AbbVie, Alzheimer’s Association; Alzheimer’s Drug Discovery Foundation; Araclon Biotech; BioClinica, Inc.; Biogen; Bristol-Myers Squibb Company; CereSpir, Inc.; Cogstate; Eisai Inc.; Elan Pharmaceuticals, Inc.; Eli Lilly and Company; EuroImmun; F. Hoffmann-La Roche Ltd. and its affiliated company Genentech, Inc.; Fujirebio; GE Healthcare; IXICO Ltd.; Janssen Alzheimer Immunotherapy Research & Development, LLC.; Johnson & Johnson Pharmaceutical Research & Development LLC.; Lumosity; Lundbeck; Merck & Co., Inc.; Meso Scale Diagnostics, LLC.; NeuroRx Research; Neurotrack Technologies; Novartis Pharmaceuticals Corporation; Pfizer Inc.; Piramal Imaging; Servier; Takeda Pharmaceutical Company; and Transition Therapeutics. The Canadian Institutes of Health Research is providing funds to support ADNI clinical sites in Canada. Private sector contributions are facilitated by the Foundation for the National Institutes of Health ( www.fnih.org ). The grantee organization is the Northern California Institute for Research and Education, and the study is coordinated by the Alzheimer’s Therapeutic Research Institute at the University of Southern California. ADNI data are disseminated by the Laboratory for Neuro Imaging at the University of Southern California.
Funding Information:
This work was partially supported by National Health Institutes (R21AG043760 and RF1AG051710 to LM, WZ, YF and YW, R01EB025032 to HZ and YW, U54EB020403 to YF and YW, R01AG031581 and P30AG19610 to RJC and EMR, 3R01HL128818-04S1 to YW), National Science Foundation (DMS-1413417 and IIS-1421165 to LM, WZ, YF, and YW) and Arizona Alzheimers Consortium (to KC, RJC, EMR and YW).
Publisher Copyright:
© 2020, Springer Science+Business Media, LLC, part of Springer Nature.
PY - 2020/10/1
Y1 - 2020/10/1
N2 - Changes in cognitive performance due to neurodegenerative diseases such as Alzheimer’s disease (AD) are closely correlated to the brain structure alteration. A univariate and personalized neurodegenerative biomarker with strong statistical power based on magnetic resonance imaging (MRI) will benefit clinical diagnosis and prognosis of neurodegenerative diseases. However, few biomarkers of this type have been developed, especially those that are robust to image noise and applicable to clinical analyses. In this paper, we introduce a variational framework to compute optimal transportation (OT) on brain structural MRI volumes and develop a univariate neuroimaging index based on OT to quantify neurodegenerative alterations. Specifically, we compute the OT from each image to a template and measure the Wasserstein distance between them. The obtained Wasserstein distance, Wasserstein Index (WI) for short to specify the distance to a template, is concise, informative and robust to random noise. Comparing to the popular linear programming-based OT computation method, our framework makes use of Newton’s method, which makes it possible to compute WI in large-scale datasets. Experimental results, on 314 subjects (140 Aβ + AD and 174 Aβ- normal controls) from the Alzheimer’s Disease Neuroimaging Initiative (ADNI) baseline dataset, provide preliminary evidence that the proposed WI is correlated with a clinical cognitive measure (the Mini-Mental State Examination (MMSE) score), and it is able to identify group difference and achieve a good classification accuracy, outperforming two other popular univariate indices including hippocampal volume and entorhinal cortex thickness. The current pilot work suggests the application of WI as a potential univariate neurodegenerative biomarker.
AB - Changes in cognitive performance due to neurodegenerative diseases such as Alzheimer’s disease (AD) are closely correlated to the brain structure alteration. A univariate and personalized neurodegenerative biomarker with strong statistical power based on magnetic resonance imaging (MRI) will benefit clinical diagnosis and prognosis of neurodegenerative diseases. However, few biomarkers of this type have been developed, especially those that are robust to image noise and applicable to clinical analyses. In this paper, we introduce a variational framework to compute optimal transportation (OT) on brain structural MRI volumes and develop a univariate neuroimaging index based on OT to quantify neurodegenerative alterations. Specifically, we compute the OT from each image to a template and measure the Wasserstein distance between them. The obtained Wasserstein distance, Wasserstein Index (WI) for short to specify the distance to a template, is concise, informative and robust to random noise. Comparing to the popular linear programming-based OT computation method, our framework makes use of Newton’s method, which makes it possible to compute WI in large-scale datasets. Experimental results, on 314 subjects (140 Aβ + AD and 174 Aβ- normal controls) from the Alzheimer’s Disease Neuroimaging Initiative (ADNI) baseline dataset, provide preliminary evidence that the proposed WI is correlated with a clinical cognitive measure (the Mini-Mental State Examination (MMSE) score), and it is able to identify group difference and achieve a good classification accuracy, outperforming two other popular univariate indices including hippocampal volume and entorhinal cortex thickness. The current pilot work suggests the application of WI as a potential univariate neurodegenerative biomarker.
KW - Alzheimer’s disease
KW - Neurodegenerative biomarker
KW - Optimal transport
KW - Wasserstein distance
UR - http://www.scopus.com/inward/record.url?scp=85083358726&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=85083358726&partnerID=8YFLogxK
U2 - 10.1007/s12021-020-09459-7
DO - 10.1007/s12021-020-09459-7
M3 - Article
C2 - 32253701
AN - SCOPUS:85083358726
SN - 1539-2791
VL - 18
SP - 531
EP - 548
JO - Neuroinformatics
JF - Neuroinformatics
IS - 4
ER -